Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists

Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene

Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722

Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2

Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077

Structure-based discovery of opioid analgesics with reduced side effects

Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D. G., Corder, G. F., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 988

Operational models of pharmacological agonism

Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951

Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance

Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802

Morphine Side Effects in β-Arrestin 2 Knockout Mice

Raehal, K. M., Walker, J. K. L., & Bohn, L. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 657

A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine

DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647

Bias factor and therapeutic window correlate to predict safer opioid analgesics

Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567 · cited 22×

Role for G protein-coupled receptor kinase in agonist-specific regulation of μ-opioid receptor responsiveness

Zhang, J., Ferguson, S. S. G., Barak, L. S., Bodduluri, S. R., Laporte, S. A., Law, P.-Y., & Caron, M. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.7157 · Cited by 505

A Simple Method for Quantifying Functional Selectivity and Agonist Bias

Kenakin, T., Watson, C., Muniz-Medina, V., Christopoulos, A., & Novick, S. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn200111m · Cited by 484

Probing the activation-promoted structural rearrangements in preassembled receptor–G protein complexes

Galès, C., Durm, J. J. J. V., Schaak, S., Pontier, S. M., Percherancier, Y., Audet, M., Paris, H., & Bouvier, M. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1134 · Cited by 480

Mini G protein probes for active G protein–coupled receptors (GPCRs) in live cells

Wan, Q., Okashah, N., Inoue, A., Nehmé, R., Carpenter, B., Tate, C. G., & Lambert, N. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001975 · Cited by 406

Quantifying Ligand Bias at Seven-Transmembrane Receptors

Rajagopal, S., Ahn, S., Rominger, D. H., Gowen-MacDonald, W., Lam, C. M., DeWire, S. M., Violin, J. D., & Lefkowitz, R. J. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072801 · Cited by 388

Biased ligands at G-protein-coupled receptors: promise and progress

Violin, J. D., Crombie, A. L., Soergel, D. G., & Lark, M. W. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.04.007 · Cited by 363

Use of a cAMP BRET Sensor to Characterize a Novel Regulation of cAMP by the Sphingosine 1-Phosphate/G13 Pathway

Jiang, L. I., Collins, J., Davis, R., Lin, K.-M., DeCamp, D., Roach, T., Hsueh, R., Rebres, R. A., Ross, E. M., Taussig, R., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609695200 · Cited by 358

Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist

Huang, P., Kehner, G. B., Cowan, A., & Liu-Chen, L.-Y. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29586-0 · Cited by 340

Buprenorphine: Clinical Pharmacokinetics in the Treatment of Opioid Dependence

Elkader, A., & Sproule, B. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544070-00001 · Cited by 335

The role of kinetic context in apparent biased agonism at GPCRs

Klein Herenbrink, C., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., Scammells, P. J., Capuano, B., Sexton, P. M., Charlton, S. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10842 · Cited by 328

Phosphorylation-deficient G-protein-biased μ-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects

Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J. T., Levitt, E. S., Williams, J. T., Christie, M. J., & Schulz, S. (2019) · Nature Communications · doi:10.1038/s41467-018-08162-1 · Cited by 309

A Genetically Encoded Biosensor Reveals Location Bias of Opioid Drug Action

Stoeber, M., Jullié, D., Lobingier, B. T., Laeremans, T., Steyaert, J., Schiller, P. W., Manglik, A., & von Zastrow, M. (2018) · Neuron · doi:10.1016/j.neuron.2018.04.021 · Cited by 286

Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile

Pergolizzi, J., Aloisi, A. M., Dahan, A., Filitz, J., Langford, R., Likar, R., Mercadante, S., Morlion, B., Raffa, R. B., Sabatowski, R., et al. (2010) · Pain Practice · doi:10.1111/j.1533-2500.2010.00378.x · Cited by 284

μ-Opioid Receptors: Correlation of Agonist Efficacy for Signalling with Ability to Activate Internalization

McPherson, J., Rivero, G., Baptist, M., Llorente, J., Al-Sabah, S., Krasel, C., Dewey, W. L., Bailey, C. P., Rosethorne, E. M., Charlton, S. J., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.066613 · Cited by 262

Morphine‐induced respiratory depression is independent of β‐arrestin2 signalling

Kliewer, A., Gillis, A., Hill, R., Schmiedel, F., Bailey, C. P., Kelly, E., Henderson, G., Christie, M. J., & Schulz, S. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15004 · Cited by 249

Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine

Kress, H. G. (2008) · European Journal of Pain · doi:10.1016/j.ejpain.2008.04.011 · Cited by 243

APOLLO‐2: A Randomized, Placebo and Active‐Controlled Phase III Study Investigating Oliceridine ( TRV 130), a G Protein–Biased Ligand at the μ‐Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty

Singla, N., Skobieranda, F. G., Soergel, D. G., Salamea, M., Burt, D. A., Demitrack, M. A., & Viscusi, E. R. (2019) · Pain Practice · doi:10.1111/papr.12801 · Cited by 199

National survey of end-of-life decisions made by UK medical practitioners

Seale, C. F. (2006) · Palliative Medicine · doi:10.1191/0269216306pm1094oa · Cited by 174

APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy

Viscusi, E. R., Skobieranda, F., Soergel, D. G., Cook, E., Burt, D. A., & Singla, N. (2019) · Journal of Pain Research · doi:10.2147/jpr.s171013 · Cited by 167

The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception

Hill, R. W., Disney, A., Conibear, A. E., Sutcliffe, K. J., Dewey, W. L., Husbands, S. M., Bailey, C. P., Kelly, E., & Henderson, G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14224 · Cited by 167

Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents

Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116689257 · Cited by 166

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Singla, N., Minkowitz, H. S., Soergel, D. G., Burt, D. A., Subach, R. A., Salamea, M., Fossler, M. J., & Skobieranda, F. G. (2017) · Journal of Pain Research · doi:10.2147/jpr.s137952 · Cited by 165

Buprenorphine Metabolites, Buprenorphine-3-glucuronide and Norbuprenorphine-3-glucuronide, Are Biologically Active

Brown, S. M., Holtzman, M. J., Kim, T., & Kharasch, E. D. (2011) · Anesthesiology · doi:10.1097/aln.0b013e318238fea0 · Cited by 164

β-arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia

Raehal, K. M., & Bohn, L. M. (2014) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-41199-1_22 · Cited by 154 · cited 1×

Progress in understanding mechanisms of opioid-induced gastrointestinal adverse effects and respiratory depression

Imam, M. Z., Kuo, A., Ghassabian, S., & Smith, M. T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.032 · Cited by 150

Molecular Physiology of Enteric Opioid Receptors

Galligan, J. J., & Akbarali, H. I. (2014) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2014.5 · Cited by 144

Why buprenorphine is so successful in treating opiate addiction in France

Fatseas, M., & Auriacombe, M. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0046-2 · Cited by 144

μ opioid receptor activation hyperpolarizes respiratory‐controlling Kölliker–Fuse neurons and suppresses post‐inspiratory drive

Levitt, E. S., Abdala, A. P., Paton, J. F. R., Bissonnette, J. M., & Williams, J. T. (2015) · The Journal of Physiology · doi:10.1113/jp270822 · Cited by 142

Efficacy and ligand bias at the μ‐opioid receptor

Kelly, E. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12222 · Cited by 139

Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics

Siuda, E. R., Carr, R., Rominger, D. H., & Violin, J. D. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.11.007 · Cited by 137

G-protein–gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids

Montandon, G., Ren, J. T., Victoria, N. C., Liu, H., Wickman, K., Greer, J. J., & Horner, R. L. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000984 · Cited by 135

A Comparision of Nalbuphine with Morphine for Analgesic Effects and Safety : Meta-Analysis of Randomized Controlled Trials

Zeng, Z., Lu, J., Shu, C., Chen, Y., Guo, T., Wu, Q., Yao, S., & Yin, P. (2015) · Scientific Reports · doi:10.1038/srep10927 · Cited by 134

Differentiation of Opioid Drug Effects by Hierarchical Multi-Site Phosphorylation

Just, S., Illing, S., Trester-Zedlitz, M., Lau, E. K., Kotowski, S. J., Miess, E., Mann, A., Doll, C., Trinidad, J. C., Burlingame, A. L., et al. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.082875 · Cited by 127

Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid μ-opioid receptor desensitization

Miess, E., Gondin, A. B., Yousuf, A., Steinborn, R., Mößlein, N., Yang, Y., Göldner, M., Ruland, J. G., Bünemann, M., Krasel, C., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aas9609 · Cited by 124

A Biased View of μ-Opioid Receptors?

Conibear, A. E., & Kelly, E. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.115956 · Cited by 115

Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics?

Madariaga‐Mazón, A., Marmolejo-Valencia, A. F., Li, Y., Toll, L., Houghten, R. A., & Martínez‐Mayorga, K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.07.002 · Cited by 112

When trafficking and signaling mix: How subcellular location shapes G protein‐coupled receptor activation of heterotrimeric G proteins

Lobingier, B. T., & von Zastrow, M. (2018) · Traffic · doi:10.1111/tra.12634 · Cited by 108

Monitoring G Protein Activation in Cells with BRET

Masuho, I., Martemyanov, K. A., & Lambert, N. A. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2914-6_8 · Cited by 107

The clinical analgesic efficacy of buprenorphine

Raffa, R. B., Haidery, M., Huang, H.-M., Kalladeen, K., Lockstein, D. E., Ono, H., Shope, M. J., Sowunmi, O. A., Tran, J. K., & Pergolizzi, J. V. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12196 · Cited by 105

Opioid-induced respiratory effects: new data on buprenorphine

Dahan, A. (2006) · Palliative Medicine · doi:10.1191/0269216306pm1126oa · Cited by 105

Sensitive and High Resolution Localization and Tracking of Membrane Proteins in Live Cells with BRET

Lan, T.-H., Liu, Q., Li, C., Wu, G., & Lambert, N. A. (2012) · Traffic · doi:10.1111/j.1600-0854.2012.01401.x · Cited by 104

Biased Signaling of the Mu Opioid Receptor Revealed in Native Neurons

Ehrlich, A. T., Semache, M., Gross, F., Fonte, D. F. D., Runtz, L., Colley, C., Mezni, A., Gouill, C. L., Lukasheva, V., Hogue, M., et al. (2019) · iScience · doi:10.1016/j.isci.2019.03.011 · Cited by 87

Biased agonism of clinically approved μ-opioid receptor agonists and TRV130 is not controlled by binding and signaling kinetics

Pedersen, M. F., Wróbel, T. M., Märcher-Rørsted, E., Pedersen, D. S., Møller, T. C., Gabriele, F., Pedersen, H., Matosiuk, D., Foster, S. R., Bouvier, M., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107718 · Cited by 86

A Novel Method for Analyzing Extremely Biased Agonism at G Protein–Coupled Receptors

Stahl, E. L., Zhou, L., Ehlert, F. J., & Bohn, L. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096503 · Cited by 80

Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain

Wolff, R. F., Aune, D., Truyers, C., Hernández, A. V., Misso, K., Riemsma, R., & Kleijnen, J. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678938 · Cited by 79

The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats

Zamarripa, C. A., Edwards, S. R., Qureshi, H. N., Yi, J. N., Blough, B. E., & Freeman, K. B. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.002 · Cited by 79

Disruption of the Na + ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor

Livingston, K. E., & Traynor, J. R. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415013111 · Cited by 74

Measurements of ligand bias and functional affinity

Kenakin, T., & Christopoulos, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3954-c2 · Cited by 74

Pharmacokinetic–Pharmacodynamic Modeling of the Effectiveness and Safety of Buprenorphine and Fentanyl in Rats

Yassen, A., Olofsen, E., Kan, J., Dahan, A., & Danhof, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9440-z · Cited by 71

Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood–brain barrier in mice

Alhaddad, H., Cisternino, S., Declèves, X., Tournier, N., Schlatter, J., Chiadmi, F., Risède, P., Smirnova, M., Besengez, C., Scherrmann, J., et al. (2012) · Critical Care Medicine · doi:10.1097/ccm.0b013e318265680a · Cited by 70

Buprenorphine Antinociception is Abolished, but Naloxone-Sensitive Reward is Retained, in μ-Opioid Receptor Knockout Mice

Ide, S., Minami, M., Satoh, M., Uhl, G. R., Sora, I., & Ikeda, K. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300463 · Cited by 70

A Continuous, Fluorescence-based Assay of µ-Opioid Receptor Activation in AtT-20 Cells

Knapman, A., Santiago, M., Du, Y. P., Bennallack, P. R., Christie, M. J., & Connor, M. A. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112461376 · Cited by 64

Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor

Thompson, G. L., Lane, J. R., Coudrat, T., Sexton, P. M., Christopoulos, A., & Canals, M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.05.014 · Cited by 57

The G‐protein‐biased agents PZM21 and TRV130 are partial agonists of μ‐opioid receptor‐mediated signalling to ion channels

Yudin, Y. K., & Rohács, T. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14702 · Cited by 48

Buprenorphine May Not Be as Safe as You Think: A Pediatric Fatality From Unintentional Exposure

Kim, H., Smiddy, M., Hoffman, R. S., & Nelson, L. S. (2012) · PEDIATRICS · doi:10.1542/peds.2012-1342 · Cited by 47

Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response

Benredjem, B., Gallion, J. M., Pelletier, D. J., Dallaire, P., Charbonneau, J., Cawkill, D., Nagi, K., Gosink, M. M., Lukasheva, V., Jenkinson, S. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11875-6 · Cited by 42

Understanding the Effect of Different Assay Formats on Agonist Parameters: A Study Using the µ-Opioid Receptor

Nickolls, S. A., Waterfield, A., Williams, R. E., & Kinloch, R. A. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111406548 · Cited by 38

A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor

Dekan, Z., Sianati, S., Yousuf, A., Sutcliffe, K. J., Gillis, A., Mallet, C., Singh, P., Jin, A., Wang, A. M., Mohammadi, S. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908662116 · Cited by 38

Ceiling respiratory depression by dezocine

Romagnoli, A., & Keats, A. S. (1984) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1984.45 · Cited by 34

RESPIRATORY FUNCTION FOLLOWING NALBUPHINE AND MORPHINE IN ANAESTHETIZED MAN

Klepper, I. D., ROSEN, M., Vickers, M. D., & MAPLESON, W. W. (1986) · British Journal of Anaesthesia · doi:10.1093/bja/58.6.625 · Cited by 34

Influence of Gαq on the Dynamics of M3-Acetylcholine Receptor–G-Protein–Coupled Receptor Kinase 2 Interaction

Wolters, V., Krasel, C., Brockmann, J., & Bünemann, M. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.094722 · Cited by 31

A Complementary Scale of Biased Agonism for Agonists with Differing Maximal Responses

Burgueño, J., Pujol, M., Monroy, X., Roche, D., Varela, M. J., Merlos, M., & Giraldo, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-15258-z · Cited by 31

Ligand bias at the μ-opioid receptor

Kelly, E. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120331 · Cited by 23

μ‐Opioid receptor activation and noradrenaline transport inhibition by tapentadol in rat single locus coeruleus neurons

Sadeghi, M., Tzschentke, T., & Christie, M. J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12566 · Cited by 20

Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms

Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232

Improving translation of animal models of addiction and relapse by reverse translation

Venniro, M., Banks, M. L., Heilig, M., Epstein, D. H., & Shaham, Y. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0378-z · Cited by 212

Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids

Vandeputte, M. M., Van Uytfanghe, K., Layle, N. K., St. Germaine, D. M., Iula, D. M., & Stove, C. P. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00064 · Cited by 161

Abnormal brain cholesterol homeostasis in Alzheimer’s disease-a targeted metabolomic and transcriptomic study

Varma, V. R., Büşra Lüleci, H., Oommen, A. M., Varma, S., Blackshear, C. T., Griswold, M. E., An, Y., Roberts, J. A., O’Brien, R., Pletnikova, O., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00064-9 · Cited by 153

The molecular pharmacology of glucagon agonists in diabetes and obesity

Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82